GlassScriptPhysician profile
Carlos A Barba
NPI 1679581359
$15,407.31
in general payments reported to CMS, 2019-2025
21 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,617 · 2020: $140 · 2021: $399 · 2022: $9,496 · 2023: $1,271 · 2024: $1,086 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.60 |
| Education | $170.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,051.50 | 2019-2024 | Da Vinci Surgical System |
| Davol INC. | $1,194.75 | 2020-2025 | Phasix Mesh, Arista Ah Flexitip |
| Lexington Medical, INC. | $582.44 | 2021-2024 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Medtronic, INC. | $359.40 | 2022-2024 | Progrip, Ligasure |
| Baxter Healthcare | $199.71 | 2019-2022 | |
| Lilly USA, LLC | $172.56 | 2025 | Zepbound, Mounjaro |
| Teleflex LLC | $140.52 | 2023-2025 | Titan Sgs Standard Gastric Stapler, Quikclot |
| Gilead Sciences, INC. | $112.66 | 2019 | |
| Covidien LP | $98.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $92.45 | 2019 | |
| Ethicon US, LLC | $79.63 | 2019-2024 | Echelon; Endopath |
| Smith+Nephew, INC. | $67.84 | 2019-2025 | Pico 14 |
| Integra Lifesciences Corporation | $53.54 | 2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Avanos Medical | $36.15 | 2023 | On-Q* Pump and Accessories |
| Takeda Pharmaceuticals U.S.A., INC. | $35.73 | 2022-2023 | Gattex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innocoll Pharmaceuticals Limited | $29.99 | 2022 | |
| Novo Nordisk INC | $28.12 | 2023 | Wegovy |
| Kerecis Limited | $23.01 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Conmed Corporation | $18.02 | 2019 | |
| Convatec INC. | $17.86 | 2024 | |
| Leica Microsystems INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Barba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.